Latest OrphAI Therapeutics News & Updates

See the latest news and media coverage for OrphAI Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
OrphAI Therapeutics

Biotech developing treatments for unmet medical needs

orphai-therapeutics.com
Headquarters
New Haven, United States
Founded year
2013
Company type
Private company
Number of employees
2–15

Latest news about OrphAI Therapeutics

Company announcements

  • OrphAI Therapeutics

    Orphai Therapeutics’ Phase 2a LAM-001 selected for ATS 2026 presentation

    Results from the multicenter open-label study of LAM-001 as add-on therapy in pulmonary hypertension patients will be presented orally at the conference in Orlando.

  • OrphAI Therapeutics

    OrphAI Therapeutics initiates Phase 2 LAM-001 trial for PAH

    The 24-week open-label study evaluates safety, tolerability, and activity in 15 adults with advanced PAH on background therapy.

  • OrphAI Therapeutics

    AI Therapeutics announces Phase 2 trial of LAM-001 at UCSF

    The investigator-initiated study evaluates safety, tolerability, and efficacy in lung transplant patients with BOS. It is a 48-week randomized, double-blind, placebo-controlled trial.

  • OrphAI Therapeutics

    OrphAI Therapeutics initiates Phase II LAM-001 trial for PAH

    The 24-week, single-arm study evaluates safety, tolerability, and activity in 15 adults with advanced PAH on background therapy. Endpoints include VO2 max and hemodynamic metrics.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about OrphAI Therapeutics

Track OrphAI Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.